Hemofarm Marked 10 Years of Successful Business in Bosnia and Herzegovina
22. February 2013.
Hemofarm d.o.o. Banja Luka, a pharmaceutical factory in Bosnia and Herzegovina, marked an important anniversary – a decade of successful business.

Together with the host, Director of Hemofarm d.o.o. Banja Luka, Mr Aleksandar Veselinović, Managing Director of Hemofarm, Mr Ronald Seeliger and the company management, the celebration of ten years of manufacturing of medicines in Banja Luka was also attended by President of Republika Srpska, Mr Milorad Dodik, as well as numerous representatives of state institutions and partner companies.

Hemofarm has been present on the BH market since 1996. A contract on joint investment between Hemofarm from Vršac and Čajavec Holding from Banja Luka was signed then. The contract was a starting point for construction of the solid dosage forms factory, which was put into operation on February 21st, 2003.

Successful manufacturer and exporter of medicines, Hemofarm d.o.o. Banja Luka is one of the bearers of pharmaceutical industry, as well as the entire economy of Bosnia and Herzegovina today.
Among other during his speech, President Dodik said “that one needed not only political, but also entrepreneurial courage to come and start business in Republika Srpska ten years ago, and Hemofarm leaders did have the sagacity to do so. If it weren’t for this,” Dodik pointed out, “not even the subsequent investments, which we now see as very successful, could probably not have been accomplished.”

“This is why this beginning was so important for the overall success of Hemofarm. The key moment was also privatisation and the fact that Hemofarm bound its business success for the team of people who worked on the accomplishment of this business success”, said Dodik.

President of Republika Srpska thanked everyone who contributed to the success of Hemofarm, insisting that this is a brand everyone could be proud of nowadays. Dodik added that the management of Hemofarm has an optimistic approach regarding Hemofarm Banja Luka.

Addressing the distinguished guests, Managing Director of Hemofarm, Mr Ronald Seeliger, among other, said the following:“It is our goal that Hemofarm be the leader in the region, and the domestic market is of strategic value for us and STADA Group has important and serious plans here. Hemofarm d.o.o. Banja Luka is a very prospective production site of great importance not only to Hemofarm, but to the entire STADA Group. In addition to the transfer of a growing number of products to this factory in Banja Luka, STADA Group has, in the course of the past 5 years alone, invested a lot into this factory, with the intention of improving the infrastructure, and expanding the portfolio with affordable, efficient and high-quality medicines of the latest generation. Care, quality, affordability and trust are our key values on which we base the strategy of business operations of Hemofarm. As a socially responsible company, we are going to continue improving our activities dedicated to the community we live and work in, dedicated to all of you for all the best“.

Director of Hemofarm d.o.o. Banja Luka, Mr Aleksandar Veselinović, said that this company has tripled its production over the last five years. He indicated that Hemofarm d.o.o. Banja Luka is among the leaders, from the financial point of view, while it holds the first place in the number of sold packs of medicines in BH.

Mr Veselinović stressed that Hemofarm d.o.o. Banja Luka exports 94 % of the products, 48 % of which to the EU, and 46 % of which to the countries of Western Balkans.

“This would not have been possible if this factory for manufacturing of medicines had not been conceived upon highest standards, supreme technological equipment, professional personnel and their commitment”, said Veselinović.

On 10,000 square meters of the production complex in Banja Luka, Hemofarm annually manufactures around 570 million tablets, i.e. more than 17 million packs.

Since August 2006, Hemofarm has been a part of German STADA Group, one of the largest generic pharmaceutical companies in Germany. With high quality and yet affordable pharmaceutical products, Hemofarm is present in 30 countries on three continents. Hemofarm manufactures medical products in 11 out of a total of 14 pharmacotherapeutic groups.